Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses BCRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BCRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jon Stonehouse | $728,466 | $0 | $0 | $11,132,458 | $1,052,633 | $0 | $37,525 | $12,951,082 |
| Former President and Chief Executive Officer | ||||||||
| Charles Gayer | 609,397 | 0 | 3,358,230 | 4,893,653 | 749,088 | 0 | 17,500 | 9,627,868 |
| President and Chief Executive Officer; Former Chief Commercial Officer | ||||||||
| Babar Ghias | 271,515 | 160,000 | 2,124,571 | 3,675,166 | 506,400 | 0 | 10,500 | 6,748,152 |
| Chief Financial Officer and Treasurer | ||||||||
| Alane Barnes | 542,519 | 0 | 867,721 | 3,634,923 | 553,369 | 0 | 17,500 | 5,616,032 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Helen Thackray | 425,999 | 0 | 1,168,791 | 1,255,458 | 756,112 | 0 | 733,264 | 4,339,624 |
| Former Chief Research and Development Officer | ||||||||
| Anthony Doyle | 151,925 | 0 | 708,694 | 1,165,816 | 0 | 0 | 114,700 | 2,141,135 |
| Former Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jon Stonehouse | $12,951,082 | — | — | — |
| Charles Gayer | 9,627,868 | — | — | — |
| Babar Ghias | 6,748,152 | — | — | — |
| Alane Barnes | 5,616,032 | — | — | — |
| Helen Thackray | 4,339,624 | — | — | — |
| Anthony Doyle | 2,141,135 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Alane Barnes | Chief Legal Officer | 2026-05-13 | A | 62,500 | $5 | $315,000 | Common | Form 4 ↗ |
| Alane Barnes | Chief Legal Officer | 2026-05-13 | D | 62,500 | 10 | 596,250 | Common | Form 4 ↗ |
| Alane Barnes | Chief Legal Officer | 2026-05-13 | D | 62,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-05-18 | D | 11,180 | 9 | 100,285 | Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-05-29 | A | 1,262 | 9 | 11,244 | Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-05-29 | A | 1,122 | 9 | 9,997 | Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-05-29 | A | 631 | 9 | 5,622 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-05-29 | A | 631 | 9 | 5,622 | Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-05-29 | A | 1,262 | 9 | 11,244 | Common | Form 4 ↗ |
| Steven K. Galson | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alan G. Levin | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Alan G. Levin | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Amy E. McKee | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Theresa M. Heggie | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Theresa M. Heggie | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| A. Machelle Sanders | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven R. Frank | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| A. Machelle Sanders | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Vincent J. Milano | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Jon P. Stonehouse | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Steven K. Galson | Director | 2026-06-11 | A | 15,294 | 0 | 0 | Common | Form 4 ↗ |
| Jill C. Milne | Director | 2026-06-11 | A | 33,540 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 629,000 | — | $286,333 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 446,250 | — | 1,999,758 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 305,995 | — | 3,341 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 297,500 | — | 957,934 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 187,562 | — | 738,178 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 500,000 | — | 278,800 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 300,000 | — | 267,672 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 870,000 | — | 2,890,014 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 675,000 | — | 1,349,613 |
| Jon Stonehouse | OPTION | 2025-12-27 | — | — | 574,500 | — | 2,360,815 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jon Stonehouse | $0 | $0 | $11,132,458 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alane Barnes | RSU | 8,500 | — | $66,300 |
| Charles Gayer | RSU | 17,000 | — | 132,600 |
| Babar Ghias | RSU | 121,700 | — | 949,260 |
| Charles Gayer | RSU | 94,463 | — | 736,811 |
| Alane Barnes | RSU | 32,000 | — | 249,600 |
| Jon Stonehouse | RSU | 31,875 | — | 248,625 |
| Jon Stonehouse | Option | 297,500 | 6.43 | — |
| Babar Ghias | Option | 355,050 | 7.13 | — |
| Alane Barnes | Option | 187,575 | 7.39 | — |
| Charles Gayer | RSU | 471,000 | — | 3,673,800 |
| Jon Stonehouse | RSU | 271,575 | — | 2,118,285 |
| Charles Gayer | Option | 986,950 | 7.13 | — |
| Babar Ghias | RSU | 147,000 | — | 1,146,600 |
| Alane Barnes | RSU | 90,525 | — | 706,095 |
| Jon Stonehouse | Option | 562,688 | 7.39 | — |
| Jon Stonehouse | RSU | 63,750 | — | 497,250 |
| Charles Gayer | Option | 195,713 | 7.39 | — |
| Jon Stonehouse | Option | 148,750 | 10.63 | — |
| Babar Ghias | Option | 305,000 | 8.55 | — |
| Alane Barnes | Option | 255,050 | 7.13 | — |
| Alane Barnes | RSU | 121,700 | — | 949,260 |
| Charles Gayer | Option | 79,250 | 6.43 | — |
| Alane Barnes | Option | 79,250 | 6.43 | — |
| Charles Gayer | RSU | 8,500 | — | 66,300 |
| Alane Barnes | Option | 39,625 | 10.63 | — |
| Charles Gayer | Option | 39,625 | 10.63 | — |
Our goal is to provide a compensation package that attracts, incentivizes, and retains employees and is designed to align employees interests with the Company s corporate strategies and business objectives and the interests of the stockholders.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Human Capital Solutions (division of Aon plc) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 126,098,528 | 56,797,571 | 959,367 | 68.95% | Passed |
| 2025 | 2025-06-12 | 143,096,094 | 6,357,577 | 302,120 | 95.75% | Passed |
| 2024 | 2024-06-12 | 138,402,008 | 6,410,647 | 584,242 | 95.57% | Passed |
| 2023 | 2023-06-13 | 112,956,369 | 10,424,056 | 844,878 | 91.55% | Passed |
| 2022 | 2022-06-07 | 97,431,771 | 10,439,088 | 570,329 | 90.32% | Passed |
| 2021 | 2021-05-25 | 68,805,650 | 4,195,252 | 13,228,045 | 94.25% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 68.95%a |
| 2025 | 2025-06-12 | 95.75%b |
| 2024 | 2024-06-12 | 95.57%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect upon these proposals.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect upon these proposals.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect upon these proposals.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 41 : 1 |
|---|---|
| CEO total compensation | $12,951,082 |
| Median employee compensation | $314,234 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nancy J. Hutson, Ph.DIndependent · Compensation | $103,817 | $225,500 | $353,569 | $0 | $0 | $682,886 |
| Vincent J. MilanoIndependent · Board Chair · Audit | 78,699 | 130,000 | 194,996 | 0 | 0 | 403,695 |
| Theresa M. HeggieIndependent · Audit · Corporate Governance and Nominating | 76,704 | 130,000 | 194,996 | 0 | 0 | 401,700 |
| Alan G. LevinIndependent · Audit (Chair) | 72,500 | 130,000 | 194,996 | 0 | 0 | 397,496 |
| Steven R. FrankIndependent · Finance · Newly elected | 29,835 | 146,663 | 219,991 | 0 | 0 | 396,489 |
| Amy E. McKee, M.DIndependent · Corporate Governance and Nominating | 65,000 | 130,000 | 194,996 | 0 | 0 | 389,996 |
| Steven K. Galson, M.D., MPHIndependent · Compensation · Corporate Governance and Nominating (Chair) | 60,588 | 130,000 | 194,996 | 0 | 0 | 385,584 |
| A. Machelle SandersIndependent · Compensation (Chair) | 60,257 | 130,000 | 194,996 | 0 | 0 | 385,253 |
| Stephen J. AselageIndependent · Not standing for re-election · Departed during FY | 33,475 | — | — | 0 | 0 | 33,475 |
| George B. AbercrombieIndependent · Departed during FY | 30,598 | — | — | 0 | 0 | 30,598 |
| Jill C. Milne, Ph.DIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Charles K. GayerEmployee director · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Jon P. StonehouseEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $325,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer ($135,000) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $611,473 |
| Equity awards (grant-date value) | $1,152,163 |
| All other compensation | $0 |
| Total cost of the board | $1,763,636 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies BioCryst Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including BioCryst Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Rhythm Pharmaceuticals | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Insmed | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | BioCryst Pharmaceuticals | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 6 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 7 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 9 | ADMA Biologics | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 10 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 11 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 12 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 13 | ACADIA Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 15 | Harmony Biosciences | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 16 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 17 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| — | SIGA Technologies | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| BioCryst Pharmaceuticals | 170% | not disclosed | not disclosed | Aon Human Capital Solutions (division of Aon plc) |
| ACADIA Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| ADMA Biologics | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Amicus Therapeutics | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals | 90.74% | not disclosed | Yes — Total Shareholder Return (TSR) relative to NASDAQ Biotechnology Index | Pay Governance |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Arrowhead Pharmaceuticals | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Catalyst Pharmaceuticals | 105% | not disclosed | not disclosed | Mercer LLC (a business of Marsh McLennan) |
| Corcept Therapeutics | 100% | not disclosed | not disclosed | not disclosed |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Harmony Biosciences | 100% | not disclosed | not disclosed | Pay Governance |
| Insmed | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Mirum Pharmaceuticals | 200% | not disclosed | No | Alpine Rewards |
| Pacira BioSciences | 90% | RSU 100 | No | Aon (Aon plc, Human Capital Solutions practice) |
| PTC Therapeutics | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Rhythm Pharmaceuticals | 120% | Options 50 · RSU 50 | No | Pay Governance LLC |
| SIGA Technologies | not disclosed | not disclosed | not disclosed | not disclosed |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jon Stonehouse | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Summary Compensation Table”. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 2 | Section 01, Charles Gayer | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Summary Compensation Table”. As printed: 9,627,868. Filing ↗machine: r15 · c48 · span 552621–552630 |
| 3 | Section 01, Babar Ghias | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Summary Compensation Table”. As printed: 6,748,152. Filing ↗machine: span 530989–530998 |
| 4 | Section 01, Alane Barnes | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Summary Compensation Table”. As printed: 5,616,032. Filing ↗machine: span 543254–543263 |
| 5 | Section 01, Helen Thackray | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Summary Compensation Table”. As printed: 4,339,624. Filing ↗machine: r9 · c48 · span 534208–534217 |
| 6 | Section 01, Anthony Doyle | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Summary Compensation Table”. As printed: 2,141,135. Filing ↗machine: r5 · c48 · span 521804–521813 |
| 7 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r7 · c17 · span 599064–599071 |
| 8 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r10 · c17 · span 609197–609204 |
| 9 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r3 · c18 · span 585456–585463 |
| 10 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r11 · c17 · span 612576–612583 |
| 11 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r12 · c17 · span 615952–615959 |
| 12 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r4 · c17 · span 588934–588941 |
| 13 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r5 · c17 · span 592310–592317 |
| 14 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r8 · c17 · span 602440–602447 |
| 15 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r6 · c17 · span 595686–595693 |
| 16 | Section 03, Jon Stonehouse OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “GRANTS OF PLAN-BASED AWARDS IN 20” · grants of plan-based awards table. Filing ↗machine: t24 · r9 · c17 · span 605818–605825 |
| 17 | Section 07, pay ratio | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “CEO Pay Ratio”. As printed: 41 : 1. Filing ↗machine: span 972792–972799 |
| 18 | Section 08, Nancy J. Hutson, Ph.D | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 682,886. Filing ↗machine: t32 · r7 · c11 · span 1061336–1061343 |
| 19 | Section 08, Vincent J. Milano | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 403,695. Filing ↗machine: t32 · r10 · c11 · span 1067471–1067478 |
| 20 | Section 08, Theresa M. Heggie | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 401,700. Filing ↗machine: t32 · r6 · c11 · span 1059251–1059258 |
| 21 | Section 08, Alan G. Levin | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 397,496. Filing ↗machine: t32 · r8 · c11 · span 1063224–1063231 |
| 22 | Section 08, Steven R. Frank | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 396,489. Filing ↗machine: t32 · r4 · c11 · span 1055457–1055464 |
| 23 | Section 08, Amy E. McKee, M.D | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 389,996. Filing ↗machine: t32 · r9 · c11 · span 1065348–1065355 |
| 24 | Section 08, Steven K. Galson, M.D., MPH | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 385,584. Filing ↗machine: t32 · r5 · c11 · span 1057359–1057366 |
| 25 | Section 08, A. Machelle Sanders | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 385,253. Filing ↗machine: t32 · r11 · c11 · span 1069365–1069372 |
| 26 | Section 08, Stephen J. Aselage | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 33,475. Filing ↗machine: t32 · r3 · c2 · span 1051921–1051927 |
| 27 | Section 08, George B. Abercrombie | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 30,598. Filing ↗machine: t32 · r2 · c2 · span 1049543–1049549 |
| 28 | Section 08, Jill C. Milne, Ph.D | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 29 | Section 08, Charles K. Gayer | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 30 | Section 08, Jon P. Stonehouse | DEF 14A | 2026-04-23 | 0001628280-26-026822 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 31 | Section 02, Alane Barnes 2026-05-13 | Form 4 | 2026-05-15 | 0000882796-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Alane Barnes 2026-05-13 | Form 4 | 2026-05-15 | 0000882796-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Alane Barnes 2026-05-13 | Form 4 | 2026-05-15 | 0000882796-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Amy E. McKee 2026-05-18 | Form 4 | 2026-05-19 | 0000882796-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Steven R. Frank 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Vincent J. Milano 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Jon P. Stonehouse 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Amy E. McKee 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Jill C. Milne 2026-05-29 | Form 4 | 2026-06-02 | 0000882796-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Steven K. Galson 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Alan G. Levin 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Alan G. Levin 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Steven R. Frank 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Jon P. Stonehouse 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Amy E. McKee 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Amy E. McKee 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Theresa M. Heggie 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Theresa M. Heggie 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, A. Machelle Sanders 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Vincent J. Milano 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Steven R. Frank 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, A. Machelle Sanders 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Vincent J. Milano 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Jon P. Stonehouse 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Jill C. Milne 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Steven K. Galson 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Jill C. Milne 2026-06-11 | Form 4 | 2026-06-15 | 0000882796-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001171843-26-004096 | Item 5.07 · say-on-pay result. As reported: 68.95% (votes for as printed: 126,098,528). Filing ↗ |
| 59 | Section 06, 2025 vote | Form 8-K | 2025-06-16 | 0001171843-25-003910 | Item 5.07 · say-on-pay result. As reported: 95.75% (votes for as printed: 143,096,094). Filing ↗ |
| 60 | Section 06, 2024 vote | Form 8-K | 2024-06-13 | 0001171843-24-003430 | Item 5.07 · say-on-pay result. As reported: 95.57% (votes for as printed: 138,402,008). Filing ↗ |
| 61 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 62 | Section 09b board cost (computed) | Computed | — | computed | Cash 611,473 + equity 1,152,163 + all other 0 = 1,763,636, summed across the director compensation table rows.machine: formula: Σ = 1,763,636 |
| 63 | PTC Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 64 | Rhythm Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals's own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 65 | Corcept Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 66 | Insmed, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 67 | BioCryst Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 68 | Pacira BioSciences, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 69 | Apellis Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 70 | Mirum Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 71 | ADMA Biologics, Section 10b CEO total | DEF 14A | 2026-04-15 | 0001140361-26-014799 | CEO total compensation as printed in ADMA Biologics's own proxy. As printed: 10,237,326. Filing ↗machine: r2 · c25 · span 619659–619670 |
| 72 | Arrowhead Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 73 | Amicus Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 74 | Travere Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 75 | ACADIA Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 76 | Dynavax Technologies, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. Filing ↗ |
| 77 | Harmony Biosciences, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 78 | Ardelyx, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 79 | Catalyst Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. Filing ↗machine: r3 · c31 · span 285833–285842 |
| 80 | Section 10a, Ardelyx reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 81 | Section 10a, Arrowhead Pharmaceuticals reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, PTC Therapeutics reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 83 | Section 10a, Rhythm Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 84 | Section 10a, Travere Therapeutics reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 85 | Section 10a, Pacira BioSciences reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 86 | Section 10a, Harmony Biosciences reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 87 | Section 10a, ACADIA Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 88 | Section 10a, Apellis Pharmaceuticals reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 89 | Section 10a, Mirum Pharmaceuticals reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals names BioCryst Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 90 | Section 10a, ADMA Biologics reciprocity | DEF 14A | — | 0001140361-26-014799 | ADMA Biologics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 91 | Section 10a, Catalyst Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 92 | Section 10a, Dynavax Technologies reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 93 | Section 10a, Amicus Therapeutics reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |
| 94 | Section 10a, Insmed reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed's most recent proxy was read; its disclosed peer group does not include BioCryst Pharmaceuticals. Filing ↗ |